lung disease
| 5 min read
Pulmonary fibrosis patients have long suffered through side effects from their drugs. That could change with the potential for new inhaled versions in clinical trials.
| 2 min read
Qureight’s Vascul8 model uses AI to analyse CT scans and identify patients at risk of residual pulmonary hypertension after surgery.
| 4 min read
Multibillion dollar oncology deals, first-in-class wins, AI scientists, and more led the news this week.
| 3 min read
Papzimeos is the first FDA-approved therapy for recurrent respiratory papillomatosis, a rare HPV-driven disease that has long forced patients into repeated surgeries.
| 2 min read
A disease once synonymous with a shortened lifespan is now a model for how drug discovery can directly alter the natural history of genetic disorders.
| 2 min read
Advanced imaging technology will support patient enrolment and provide detailed analysis of anatomical lung changes, helping evaluate the efficacy of CAL101 in idiopathic pulmonary fibrosis.
| 2 min read
First DPP1 inhibitor drug milestone marks a long-awaited breakthrough for NCFB patients.
| 7 min read
Synthetic control arms are emerging as a valuable solution for clinical trials where using traditional placebo groups is difficult, unethical, or impractical.
| 2 min read
Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies
| 5 min read
Explore how the immune system battles mold in lungs. A new study reveals a key cytokine, GM-CSF, helps immune cells clear the dangerous fungal spores.
